AGI has built advanced robotic-assisted and laparoscopic surgical platforms that dramatically expand the scope of minimally invasive preclinical research in NHPs. These capabilities reduce perioperative stress, minimize recovery times, and improve overall welfare while also providing study sponsors with data that more closely replicates modern clinical workflows. Our robotic systems combine precision-controlled instrumentation, high-definition visualization, and integrated telemetry to enable exacting interventions across oncology, cardiovascular, gastrointestinal, and orthopedic applications. Laparoscopic models include targeted organ resections, catheter-based ablations, localized drug delivery, and long-term implant evaluations.

 

Each study is designed to generate high-quality data on safety, biodistribution, expression, and durability, supported by complementary histology, biomarker profiling, and chronic survival endpoints. In addition, our robotic and laparoscopic programs are conducted under validated GLP protocols with full perioperative monitoring, ensuring data that is reproducible, auditable, and regulator-ready. By merging advanced technology, refined surgical skill, and comprehensive compliance oversight, AGI empowers sponsors to move rapidly from prototype evaluation to regulatory submission, while maintaining the highest standards of scientific and ethical rigor.